IBB Full Holdings List
All 254 positions in iShares Biotechnology ETF from iShares, as of Mar 31, 2026, sorted by portfolio weight. Cash, collateral and derivative positions (9.8% of weight) are excluded. For the top holdings with charts and stats, see the IBB overview →
All 254 holdings
| # | Holding | Weight |
|---|---|---|
| 1 | GILDGilead Sciences, Inc. | 7.75% |
| 2 | AMGNAmgen, Inc. | 7.51% |
| 3 | VRTXVertex Pharmaceuticals, Inc. | 7.44% |
| 4 | REGNRegeneron Pharmaceuticals, Inc. | 7.21% |
| 5 | ALNYAlnylam Pharmaceuticals, Inc. | 3.99% |
| 6 | INSMInsmed, Inc. | 3.20% |
| 7 | ARGXArgenx SE | 3.07% |
| 8 | BIIBBiogen, Inc. | 2.46% |
| 9 | NTRANatera, Inc. | 2.41% |
| 10 | UTHRUnited Therapeutics Corp. | 2.30% |
| 11 | ONCBeOne Medicines Ltd. | 1.93% |
| 12 | INCYIncyte Corp. | 1.70% |
| 13 | MRNAModerna, Inc. | 1.68% |
| 14 | ILMNIllumina, Inc. | 1.68% |
| 15 | RVMDRevolution Medicines, Inc. | 1.54% |
| 16 | ROIVRoivant Sciences Ltd. | 1.24% |
| 17 | NBIXNeurocrine Biosciences, Inc. | 1.18% |
| 18 | GMABGenmab A/S | 1.17% |
| 19 | BBIOBridgebio Pharma, Inc. | 1.13% |
| 20 | IONSIonis Pharmaceuticals, Inc. | 1.11% |
| 21 | MEDPMedpace Holdings, Inc. | 1.00% |
| 22 | MDGLMadrigal Pharmaceuticals, Inc. | 1.00% |
| 23 | EXELExelixis, Inc. | 0.99% |
| 24 | BMRNBioMarin Pharmaceutical, Inc. | 0.98% |
| 25 | Ascendis Pharma A/S | 0.96% |
| 26 | PRAXPraxis Precision Medicines, Inc. | 0.77% |
| 27 | CRLCharles River Laboratories International, Inc. | 0.77% |
| 28 | ARWRArrowhead Pharmaceuticals, Inc. | 0.75% |
| 29 | PCVXVaxcyte, Inc. | 0.75% |
| 30 | TECHBio-Techne Corp. | 0.74% |
| 31 | CYTKCytokinetics, Inc. | 0.73% |
| 32 | HALOHalozyme Therapeutics, Inc. | 0.69% |
| 33 | AXSMAxsome Therapeutics, Inc. | 0.66% |
| 34 | BNTXBioNTech SE | 0.66% |
| 35 | KRYSKrystal Biotech, Inc. | 0.60% |
| 36 | PTGXProtagonist Therapeutics, Inc. | 0.58% |
| 37 | RGENRepligen Corp. | 0.58% |
| 38 | KYMRKymera Therapeutics, Inc. | 0.53% |
| 39 | ALKSAlkermes plc | 0.53% |
| 40 | RYTMRhythm Pharmaceuticals, Inc. | 0.51% |
| 41 | ABVXAbivax SA | 0.50% |
| 42 | PTCTPTC Therapeutics, Inc. | 0.50% |
| 43 | COGTCogent Biosciences, Inc. | 0.48% |
| 44 | ACLXArcellx, Inc. | 0.47% |
| 45 | 430Terns Pharmaceuticals, Inc. | 0.46% |
| 46 | Nuvalent, Inc., Class A | 0.45% |
| 47 | MIRMMirum Pharmaceuticals, Inc. | 0.45% |
| 48 | TEMTempus AI, Inc., Class A | 0.43% |
| 49 | XENEXenon Pharmaceuticals, Inc. | 0.43% |
| 50 | AM6Amicus Therapeutics, Inc. | 0.41% |
| 51 | 1CGCRISPR Therapeutics AG | 0.39% |
| 52 | 1JKApellis Pharmaceuticals, Inc. | 0.39% |
| 53 | APGEApogee Therapeutics, Inc. | 0.37% |
| 54 | SRRKScholar Rock Holding Corp. | 0.36% |
| 55 | ACADACADIA Pharmaceuticals, Inc. | 0.34% |
| 56 | BRKRBruker Corp. | 0.34% |
| 57 | CRNXCrinetics Pharmaceuticals, Inc. | 0.32% |
| 58 | CGONCG oncology, Inc. | 0.32% |
| 59 | SYRESpyre Therapeutics, Inc. | 0.30% |
| 60 | ERASErasca, Inc. | 0.28% |
| 61 | TARSTarsus Pharmaceuticals, Inc. | 0.26% |
| 62 | TWSTTwist Bioscience Corp. | 0.26% |
| 63 | 260Centessa Pharmaceuticals plc | 0.25% |
| 64 | IDYAIdeaya Biosciences, Inc. | 0.25% |
| 65 | DNLIDenali Therapeutics, Inc. | 0.25% |
| 66 | TVTXTravere Therapeutics, Inc. | 0.25% |
| 67 | IBRXImmunityBio, Inc. | 0.24% |
| 68 | ARQTArcutis Biotherapeutics, Inc. | 0.24% |
| 69 | VCYTVeracyte, Inc. | 0.23% |
| 70 | GPCRStructure Therapeutics, Inc. | 0.23% |
| 71 | EWTXEdgewise Therapeutics, Inc. | 0.22% |
| 72 | TXG10X Genomics, Inc., Class A | 0.22% |
| 73 | LEGNLegend Biotech Corp. | 0.22% |
| 74 | NAMSNewamsterdam Pharma Co. NV | 0.21% |
| 75 | VERAVera Therapeutics, Inc., Class A | 0.21% |
| 76 | DYNDyne Therapeutics, Inc. | 0.20% |
| 77 | BEAMBeam Therapeutics, Inc. | 0.20% |
| 78 | BCRXBioCryst Pharmaceuticals, Inc. | 0.20% |
| 79 | KODKodiak Sciences, Inc. | 0.20% |
| 80 | SRPTSarepta Therapeutics, Inc. | 0.20% |
| 81 | CAICaris Life Sciences, Inc. | 0.20% |
| 82 | IMVTImmunovant, Inc. | 0.19% |
| 83 | ADMAADMA Biologics, Inc. | 0.19% |
| 84 | ADPTAdaptive Biotechnologies Corp. | 0.19% |
| 85 | SMMTSummit Therapeutics, Inc. | 0.19% |
| 86 | ORKAOruka Therapeutics, Inc. | 0.18% |
| 87 | SNDXSyndax Pharmaceuticals, Inc. | 0.18% |
| 88 | TNGXTango Therapeutics, Inc. | 0.18% |
| 89 | RAREUltragenyx Pharmaceutical, Inc. | 0.18% |
| 90 | IRONDisc Medicine, Inc. | 0.17% |
| 91 | AGIOAgios Pharmaceuticals, Inc. | 0.17% |
| 92 | GRALGRAIL, Inc. | 0.17% |
| 93 | DFTXDefinium Therapeutics, Inc. | 0.16% |
| 94 | ZYMEZymeworks, Inc. | 0.16% |
| 95 | RCUSArcus Biosciences, Inc. | 0.16% |
| 96 | AUPHAurinia Pharmaceuticals, Inc. | 0.16% |
| 97 | ELVNEnliven Therapeutics, Inc. | 0.16% |
| 98 | Day One Biopharmaceuticals, Inc. | 0.15% |
| 99 | VCELVericel Corp. | 0.15% |
| 100 | MLYSMineralys Therapeutics, Inc. | 0.15% |
| 101 | ALMSAlumis, Inc. | 0.14% |
| 102 | ZLABZai Lab Ltd. | 0.14% |
| 103 | NRIXNurix Therapeutics, Inc. | 0.14% |
| 104 | STOKStoke Therapeutics, Inc. | 0.13% |
| 105 | NTLAIntellia Therapeutics, Inc. | 0.13% |
| 106 | ANABAnaptysBio, Inc. | 0.13% |
| 107 | RXRXRecursion Pharmaceuticals, Inc., Class A | 0.13% |
| 108 | TYRATyra Biosciences, Inc. | 0.13% |
| 109 | RLAYRelay Therapeutics, Inc. | 0.12% |
| 110 | AMLXAmylyx Pharmaceuticals, Inc. | 0.12% |
| 111 | NVAXNovavax, Inc. | 0.12% |
| 112 | IOVAIovance Biotherapeutics, Inc. | 0.11% |
| 113 | WVEWaVe Life Sciences Ltd. | 0.10% |
| 114 | IMCRImmunocore Holdings plc | 0.10% |
| 115 | NVCRNovocure Ltd. | 0.10% |
| 116 | LKFTGalapagos NV | 0.10% |
| 117 | GRFSGrifols SA | 0.10% |
| 118 | BHVNBiohaven Ltd. | 0.10% |
| 119 | NUVBNuvation Bio, Inc., Class A | 0.09% |
| 120 | ATAIAtaiBeckley, Inc. | 0.09% |
| 121 | TSHATaysha Gene Therapies, Inc. | 0.09% |
| 122 | SIONSionna Therapeutics, Inc. | 0.09% |
| 123 | TRVITrevi Therapeutics, Inc. | 0.09% |
| 124 | MESOMesoblast Ltd. | 0.09% |
| 125 | CRVSCorvus Pharmaceuticals, Inc. | 0.09% |
| 126 | OLMAOlema Pharmaceuticals, Inc. | 0.08% |
| 127 | RAPPRapport Therapeutics, Inc. | 0.08% |
| 128 | QUREuniQure NV | 0.08% |
| 129 | GERNGeron Corp. | 0.08% |
| 130 | FTREFortrea Holdings, Inc. | 0.08% |
| 131 | VIRVir Biotechnology, Inc. | 0.08% |
| 132 | XNCRXencor, Inc. | 0.08% |
| 133 | ABCLAbCellera Biologics, Inc. | 0.07% |
| 134 | MBXMBX Biosciences, Inc. | 0.07% |
| 135 | MAZEMaze Therapeutics, Inc. | 0.07% |
| 136 | CDNACareDx, Inc. | 0.07% |
| 137 | TBPHTheravance Biopharma, Inc. | 0.07% |
| 138 | GLUEMonte Rosa Therapeutics, Inc. | 0.07% |
| 139 | 4XC1KalVista Pharmaceuticals, Inc. | 0.07% |
| 140 | JANXJanux Therapeutics, Inc. | 0.07% |
| 141 | PHVSPharvaris NV | 0.07% |
| 142 | MNKDMannKind Corp. | 0.07% |
| 143 | ORICORIC Pharmaceuticals, Inc. | 0.07% |
| 144 | CSTLCastle Biosciences, Inc. | 0.07% |
| 145 | ANNXAnnexon, Inc. | 0.07% |
| 146 | URGNUroGen Pharma Ltd. | 0.06% |
| 147 | KURAKura Oncology, Inc. | 0.06% |
| 148 | INBXInhibrx Biosciences, Inc. | 0.06% |
| 149 | STVNStevanato Group SpA | 0.06% |
| 150 | ABUSArbutus Biopharma Corp. | 0.06% |
| 151 | SEPNSepterna, Inc. | 0.06% |
| 152 | ANROAlto Neuroscience, Inc. | 0.06% |
| 153 | BCAXBicara Therapeutics, Inc. | 0.06% |
| 154 | GHRSGH Research plc | 0.06% |
| 155 | AVBPArriVent Biopharma, Inc. | 0.06% |
| 156 | CTMXCytomX Therapeutics, Inc. | 0.06% |
| 157 | CGEMCullinan Therapeutics, Inc. | 0.06% |
| 158 | REPLReplimune Group, Inc. | 0.05% |
| 159 | ARVNArvinas, Inc. | 0.05% |
| 160 | PGENPrecigen, Inc. | 0.05% |
| 161 | SVRASavara, Inc. | 0.05% |
| 162 | IRWDIronwood Pharmaceuticals, Inc., Class A | 0.05% |
| 163 | Phathom Pharmaceuticals, Inc. | 0.05% |
| 164 | Zevra Therapeutics, Inc. | 0.05% |
| 165 | Cytek Biosciences, Inc. | 0.05% |
| 166 | MGTXMeiraGTx Holdings plc | 0.05% |
| 167 | SPRYARS Pharmaceuticals, Inc. | 0.05% |
| 168 | BioAge Labs, Inc. | 0.05% |
| 169 | SANASana Biotechnology, Inc. | 0.04% |
| 170 | RIGLRigel Pharmaceuticals, Inc. | 0.04% |
| 171 | ZBIOZenas Biopharma, Inc. | 0.04% |
| 172 | CMPSCompass Pathways plc | 0.04% |
| 173 | OPKO Health, Inc. | 0.04% |
| 174 | Fulcrum Therapeutics, Inc. | 0.04% |
| 175 | SLDBSolid Biosciences, Inc. | 0.04% |
| 176 | FDMT4D Molecular Therapeutics, Inc. | 0.04% |
| 177 | PRTAProthena Corp. plc | 0.04% |
| 178 | EBSEmergent BioSolutions, Inc. | 0.04% |
| 179 | MYGNMyriad Genetics, Inc. | 0.04% |
| 180 | ABSIAbsci Corp. | 0.04% |
| 181 | BBOTBridgeBio Oncology Therapeutics, Inc. | 0.04% |
| 182 | CATXPerspective Therapeutics, Inc. | 0.04% |
| 183 | Aclaris Therapeutics, Inc. | 0.04% |
| 184 | ALTAltimmune, Inc. | 0.04% |
| 185 | VNDAVanda Pharmaceuticals, Inc. | 0.03% |
| 186 | ALLOAllogene Therapeutics, Inc. | 0.03% |
| 187 | RGNXREGENXBIO, Inc. | 0.03% |
| 188 | Rocket Pharmaceuticals, Inc. | 0.03% |
| 189 | PACBPacific Biosciences of California, Inc. | 0.03% |
| 190 | LXEOLexeo Therapeutics, Inc. | 0.03% |
| 191 | Contineum Therapeutics, Inc., Class A | 0.03% |
| 192 | Alvotech SA | 0.03% |
| 193 | Enanta Pharmaceuticals, Inc. | 0.03% |
| 194 | Lineage Cell Therapeutics, Inc. | 0.03% |
| 195 | Standard BioTools, Inc. | 0.03% |
| 196 | ADC Therapeutics SA | 0.03% |
| 197 | Design Therapeutics, Inc. | 0.03% |
| 198 | PSNLPersonalis, Inc. | 0.03% |
| 199 | Atea Pharmaceuticals, Inc. | 0.03% |
| 200 | PRMEPrime Medicine, Inc. | 0.03% |
| 201 | Keros Therapeutics, Inc. | 0.03% |
| 202 | Fulgent Genetics, Inc. | 0.03% |
| 203 | Tectonic Therapeutic, Inc. | 0.03% |
| 204 | Aura Biosciences, Inc. | 0.03% |
| 205 | KYTXKyverna Therapeutics, Inc. | 0.03% |
| 206 | MRVIMaravai LifeSciences Holdings, Inc., Class A | 0.03% |
| 207 | Immuneering Corp., Class A | 0.03% |
| 208 | Anavex Life Sciences Corp. | 0.03% |
| 209 | Entrada Therapeutics, Inc. | 0.02% |
| 210 | DNAGinkgo Bioworks Holdings, Inc. | 0.02% |
| 211 | Upstream Bio, Inc. | 0.02% |
| 212 | Neurogene, Inc. | 0.02% |
| 213 | LENZ Therapeutics, Inc. | 0.02% |
| 214 | Autolus Therapeutics plc | 0.02% |
| 215 | Editas Medicine, Inc. | 0.02% |
| 216 | CABACabaletta Bio, Inc. | 0.02% |
| 217 | C4 Therapeutics, Inc. | 0.02% |
| 218 | Larimar Therapeutics, Inc. | 0.02% |
| 219 | ARCTArcturus Therapeutics Holdings, Inc. | 0.02% |
| 220 | CADLCandel Therapeutics, Inc. | 0.02% |
| 221 | OmniAb, Inc. | 0.02% |
| 222 | NBPNovaBridge Biosciences | 0.02% |
| 223 | Voyager Therapeutics, Inc. | 0.02% |
| 224 | AC Immune SA | 0.01% |
| 225 | Bicycle Therapeutics plc | 0.01% |
| 226 | Caribou Biosciences, Inc. | 0.01% |
| 227 | Codexis, Inc. | 0.01% |
| 228 | Lyell Immunopharma, Inc. | 0.01% |
| 229 | Cellectis SA | 0.01% |
| 230 | Foghorn Therapeutics, Inc. | 0.01% |
| 231 | Quanterix Corp. | 0.01% |
| 232 | SGMTSagimet Biosciences, Inc., Class A | 0.01% |
| 233 | QSIQuantum-Si, Inc. | 0.01% |
| 234 | Silence Therapeutics plc | 0.01% |
| 235 | Tenaya Therapeutics, Inc. | 0.01% |
| 236 | Neumora Therapeutics, Inc. | 0.01% |
| 237 | PepGen, Inc. | 0.01% |
| 238 | Humacyte, Inc. | 0.01% |
| 239 | Black Diamond Therapeutics, Inc. | 0.01% |
| 240 | Pyxis Oncology, Inc. | 0.01% |
| 241 | Gossamer Bio, Inc. | 0.01% |
| 242 | Jyong Biotech Ltd. | 0.01% |
| 243 | Aardvark Therapeutics, Inc. | 0.00% |
| 244 | Akero Therapeutics, Inc., CVR | 0.00% |
| 245 | Immutep Ltd. | 0.00% |
| 246 | Alpha Teknova, Inc. | 0.00% |
| 247 | Contra Chinook Therape, CVR | 0.00% |
| 248 | Cargo Therapeutics, Inc., CVR | 0.00% |
| 249 | Fusion Pharmaceuticals, Inc., CVR | 0.00% |
| 250 | 2200964DOmniAb, Inc., 15.00 Earnout Shares | 0.00% |
| 251 | Third Harmonic Bio, Inc. | 0.00% |
| 252 | Cartesian Therapeutics, Inc. | 0.00% |
| 253 | Akouos, Inc., CVR | 0.00% |
| 254 | 2200963DOmniAb, Inc., 12.50 Earnout Shares | 0.00% |
Listed weights cover 99.9% of the portfolio. Source: official issuer holdings and SEC N-PORT filings. Holdings change — verify with the issuer before making decisions.